Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37409171)
Watch
English
Targeting mTOR with rapamycin: one dose does not fit all
scientific article published on 02 April 2009
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Targeting mTOR with rapamycin: one dose does not fit all
(English)
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
main subject
sirolimus
1 reference
based on heuristic
inferred from title
author name string
David A Foster
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
Alfredo Toschi
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
2 April 2009
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
published in
Cell Cycle
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
volume
8
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
issue
7
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
page(s)
1026-1029
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
cites work
Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
mTOR signaling: PLD takes center stage
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Phospholipase D1 is an effector of Rheb in the mTOR pathway.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Defining the role of mTOR in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
mTOR and cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Imatinib as a paradigm of targeted therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Will mTOR inhibitors make it as cancer drugs?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Phosphatidic acid-mediated mitogenic activation of mTOR signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
6 September 2017
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
14 September 2017
A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
14 September 2017
HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
14 September 2017
Alternative phospholipase D/mTOR survival signal in human breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
14 September 2017
Phase I study of everolimus in pediatric patients with refractory solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
2 September 2018
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
2 September 2018
Phospholipase D confers rapamycin resistance in human breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
2 September 2018
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778016
retrieved
2 September 2018
Identifiers
DOI
10.4161/CC.8.7.8044
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
PMCID
2778016
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
PubMed ID
19270529
1 reference
stated in
Europe PubMed Central
PMCID
2778016
retrieved
20 August 2017
ResearchGate publication ID
24185996
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
